Clinical outcomes of corticosteroids for COVID-19 patients at the National Center for Global Health and Medicine during the first wave of infection.
Not Applicable
- Conditions
- COVID-19
- Registration Number
- JPRN-UMIN000047184
- Brief Summary
Between February and April 2020, 110 patients were diagnosed with COVID-19. Despite poor conditions during admission into the steroid group, there were no statistical differences in clinical course between both groups, as measured using the scale. There were no statistical differences between the two groups in the number of days to fever resolution or negative polymerase chain reaction results.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 110
Inclusion Criteria
Not provided
Exclusion Criteria
Cases in which corticosteroids were not used in doses consistent with ARDS or severe pneumonia
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improved scores for 7-category ordinary scale
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie corticosteroid efficacy in severe COVID-19 respiratory failure?
How do corticosteroids compare to remdesivir in reducing ICU admission for first-wave hospitalized COVID-19 patients?
Which inflammatory biomarkers (e.g., IL-6, CRP) predict response to corticosteroid therapy in early-stage COVID-19?
What adverse events are associated with corticosteroid use in elderly COVID-19 patients with comorbidities?
How do corticosteroid regimens interact with antiviral therapies like favipiravir in managing SARS-CoV-2 viral load?